EUVIMEDEUVIMED entdecken
Crossref

Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor

Jason D Shields iD, David Baker, Amber Y S Balazs iD, Gayathri Bommakanti, Robert Casella, Shenggen Cao, Steve Cook, Randolph A Escobar iD, Stephen Fawell, Francis D Gibbons, Kathryn A Giblin, Frederick W Goldberg iD und 48 weitere

Journal of Medicinal Chemistry · 27.02.2025 · 68 (4) · 4582-4595

DOI: 10.1021/acs.jmedchem.4c02631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.02.2025. Verfasst von Jason D Shields und 59 weiteren Autor:innen. Beteiligte Einrichtung: Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States. Hauptthemen laut MEDLINE: Pyrazines, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the T cell receptor signaling pathway and is therefore a target of interest for immunooncology. Nonselective HPK1 inhibitors may affect other kinase components of T cell activation, blunting the beneficial impact of enhanced T cell activity that results from HPK1 inhibition itself. Here, we report the discovery of pyrazine carboxamide HPK1 inhibitors and their optimization through structure-based drug design to afford a highly selective HPK1 inhibitor, compound 24 (AZ3246). This compound induces IL-2 secretion in T cells with an EC50 of 90 nM without inhibiting antagonistic kinases, exhibits pharmacokinetic properties consistent with oral dosing, and demonstrates antitumor activity in the EMT6 syngeneic mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinesProtein Kinase InhibitorsProtein Serine-Threonine KinasesAnimalsMiceHumansStructure-Activity RelationshipAntineoplastic AgentsDrug DiscoveryT-LymphocytesRats

Substanzen

PyrazinesProtein Kinase InhibitorsProtein Serine-Threonine Kinaseshematopoietic progenitor kinase 1Antineoplastic Agents

Autor:innen und Institutionen

  • Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.
  • Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
  • Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.
  • Pharmaceutical Sciences, R&D, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.

ORCID-Profile: Jason D Shields, Amber Y S Balazs, Randolph A Escobar, Frederick W Goldberg, Niresh Hariparsad, Jason G Kettle, Anthony J Metrano, Adelphe M Mfuh, Kevin J Robbins, Marianne Schimpl, Alwin G Schuller, James E Sheppeck, Kun Song, David J Wagner, Andrew X Zhang

Zitieren

APA

Shields, J. D., Baker, D., Balazs, A. Y. S., Bommakanti, G., Casella, R., Cao, S., Cook, S., Escobar, R. A., Fawell, S., Gibbons, F. D., Giblin, K. A., Goldberg, F. W., Gosselin, E., Grebe, T., Hariparsad, N., Hatoum-Mokdad, H., Howells, R., Hughes, S. J., Jackson, A., …, & Zhang, A. X. (2025). Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor. Journal of Medicinal Chemistry, 68(4), 4582-4595. https://doi.org/10.1021/acs.jmedchem.4c02631

Vancouver

Shields JD, Baker D, Balazs AYS, Bommakanti G, Casella R, Cao S, et al. Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor. Journal of Medicinal Chemistry. 2025;68(4):4582-4595. doi:10.1021/acs.jmedchem.4c02631

BibTeX
@article{Shields2025,
  author = {Shields, Jason D and Baker, David and Balazs, Amber Y S and Bommakanti, Gayathri and Casella, Robert and Cao, Shenggen and Cook, Steve and Escobar, Randolph A and Fawell, Stephen and Gibbons, Francis D and Giblin, Kathryn A and Goldberg, Frederick W and Gosselin, Eric and Grebe, Tyler and Hariparsad, Niresh and Hatoum-Mokdad, Holia and Howells, Rachel and Hughes, Samantha J and Jackson, Anne and Karapa Reddy, Iswarya and Kettle, Jason G and Lamont, Gillian M and Lamont, Scott and Li, Min and Lill, Sten O Nilsson and Mele, Deanna A and Metrano, Anthony J and Mfuh, Adelphe M and Morrill, Lucas A and Peng, Bo and Pflug, Alexander and Proia, Theresa A and Rezaei, Hadi and Richards, Ryan and Richter, Magdalena and Robbins, Kevin J and San Martin, Maryann and Schimpl, Marianne and Schuller, Alwin G and Sha, Li and Shen, Minhui and Sheppeck, James E and Singh, Meha and Stokes, Stephen and Song, Kun and Sun, Yuanyuan and Tang, Haoran and Wagner, David J and Wang, Jianyan and Wang, Yanjun and Wilson, David M and Wu, Allan and Wu, Chengyan and Wu, Dedong and Wu, Ye and Xu, Kevin and Yang, Yue and Yao, Tieguang and Ye, Minwei and Zhang, Andrew X},
  title = {Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {4},
  pages = {4582--4595},
  doi = {10.1021/acs.jmedchem.4c02631}
}
Kostenlos starten →